Full Press Release Details
Inc. Regains Compliance with NASDAQ Listing Standards
Lake City, Utah - Feb 22, 2019 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a
unique, patented platform for the development of molecular diagnostic tests, announced today that it has received written notice
from the Nasdaq Stock Market ("Nasdaq") Listing Qualifications Staff on February 19, 2019, indicating that the Company
has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Capital Markets Listing
Rule 5550(b)(1). Nasdaq considers the matter closed.
Co-Diagnostics, Inc.:
Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics
technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic
acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers
for use in industries other than infectious disease and license the use of those tests to specific customers.
press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes,"
"expects," "estimates," "intends," "may," "plans," "will"
and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as
they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements
in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration
of initiatives in liquid biopsy and SNP detection, (iv) use of the Company's liquid biopsy tests by laboratories, (v) capital
resources and runway needed to advance the Company's products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company's balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated
or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on
any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating
to matters discussed in this press release, except as may be required by applicable securities laws.